Thermo Fisher Scientific (TMO) Inks Deal to Manufacture Adial Pharmaceuticals ADO4

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of Goldman Sachs’ top healthcare stock picks. On June 25, the company confirmed it had inked a strategic partnership with Adial Pharmaceuticals (NASDAQ:ADIL).

Under the terms of the agreement, Thermo Fisher is to become the Contract Development and Manufacturing Organization (CDMO) for AD04 Drug products. The product is being developed as a targeted therapeutic agent for the treatment of Alcohol Use Disorder.

On the other hand, Cambrex is to become the drug substance CDMO and supplier of Ondansetron API. The agreements cover all phases of manufacturing for both clinical supplies for ADO4. In addition, the agreements mark the initial steps AS Adial Pharmaceutical plants to conduct ADO4 clinical trials.

“The combination of Thermo Fisher and Cambrex makes for a strong collaboration for Adial in our quest to develop AD04 for the treatment of AUD. Choosing a contract manufacturer that can meet our timelines for starting the clinical program is paramount,” Cary Claiborne, President and Chief Executive Officer of Adial, commented.

Thermo Fisher Scientific Inc. (NYSE:TMO) is a healthcare company that provides analytical instruments, specialty diagnostics, laboratory equipment, pharmaceutical and biotechnology services, and clinical development solutions.

While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Green Energy Penny Stocks to Buy Right Now and 10 Most Popular AI Penny Stocks to Buy According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.